Advocacy intelligence hub — real-time data for patient organizations
Iplex: FDA approved
Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone
Increlex: FDA approved
Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
Protropin: FDA approved
1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's synd
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Iplex
Insmed, Inc.
Protropin
Genentech, Inc.
Patient Assistance Programs1
Increlex
Eton Pharmaceuticals, Inc.
Increlex
(Mecasermin)Orphan drugEton Pharmaceuticals, Inc.
12.1 Mechanism of Action Insulin-like growth factor-1 (IGF-1) is a key hormonal mediator on statural growth. Under normal circumstances, growth hormon...
Protropin
(Somatrem for injection)Orphan drugGenentech, Inc.
View all Growth hormone insensitivity syndrome specialists →